QT IMAGING HOLDINGS, INC. (QTI) stock intrinsic value fair value estimate & owner earnings analysis

What the business is. QT Imaging makes the QT Breast Scanner, a breast acoustic CT (transmission ultrasound) system that images the breast without radiation or compression, plus a cloud software subscription. It became public in March 2024 by merging into a blank-check company, traded over the counter, did a 1-for-3 reverse split in October 2025 and moved to the Nasdaq Capital Market in January 2026. Scanners are built in Novato, California and, since March 2025, also by Canon Medical Systems. In 2025 and the first half of 2026, 98-100% of revenue came from one buyer, NXC Imaging (a Canon Medical USA subsidiary), which resells the scanners in the United States. NXC is not obligated to buy any particular quantity beyond the minimums in its agreement, and that agreement expires on December 31, 2026. What it has actually earned. The company has never produced positive cash earnings. Measured as operating cash flow, stripped of working-capital swings, after stock compensation and the capital spending needed to maintain the business, it lost about $4.5 million in 2023 (before commercial launch), $8.8 million in 2024 and $4.7 million in 2025 ($1.43, $1.32 and $0.45 per share). Revenue rose from $4.9 million in 2024 to $18.9 million in 2025 and $14.0 million in the first half of 2026, but the operating loss in the first half of 2026 ($4.2 million) was twice the prior-year half, because operating expenses were raised to about a $20 million annual rate while gross margin stayed near 41%. At that margin the company needs roughly $48 million of annual revenue to break even. The large reported net losses ($21.1 million in 2025, $14.5 million in the first half of 2026) are mostly non-cash charges from warrants and from refinancing its loan, which we did not count against the business. Interest on its main loan is paid in kind (added to the balance) rather than in cash. How we valued it. We valued the operating business first and then subtracted what it owes, at a flat 6% discount rate. We credited only revenue backed by signed agreements: NXC's 2026 minimums (up to $28.5 million), Gulf Medical in Saudi Arabia (92 scanners over 2026-2028, local approval received June 2026) and Al Naghi Medical in the UAE (43 scanners over 2026-2028, approved March 2026). Those minimums are soft: if the Gulf distributors fall short, the company's remedy is only to end their exclusivity, and first-half 2026 sales ran well below the pace needed to meet the 2026 minimums. Nothing we can point to carries the business beyond 2028-2029, so each case ends there, with the business recovering its receivables and inventory. We did not assume cost cuts, higher margins or new markets, because none is evidenced. What it owes. At June 30, 2026 the company held $10.9 million of cash against about $11.4 million owed on the Lynrock Lake term loan, which in May 2026 was extended to March 31, 2029 with its rate raised from 10% to 12%, compounding into the balance, plus $3.9 million of related-party notes due October 2027. Because the loan compounds at twice our discount rate for almost three more years, we count it at about $13.2 million. Net of cash, the company owes about $6.2 million. Lynrock also holds a warrant for about 25.3 million shares at $0.96, nearly twice today's 13.8 million shares outstanding. It only matters if the shares are worth more than $0.96, which none of our cases reach, but it caps what existing shareholders can gain if the business succeeds. We used about 16.4 million shares, including pre-funded warrants. Base case. Revenue of about $30 million in 2026 and $32-34 million in 2027-2028. NXC keeps buying at roughly its 2025 level after its agreement ends, and the Gulf distributors take about 60% of their minimums. The cost base stays at the 2026 level, so the business loses about $6-7 million a year through 2028, then recovers about $5 million of working capital. The business is worth about -$11 million. After $6.2 million of net debt, that is about -$17 million, or -$1.04 per share. On current cash the company would need new equity by late 2027, so shareholders would have to keep putting money in. Bear case. NXC does not renew at the end of 2026, which is a real risk because it is the only meaningful customer and its contract is expiring. The new Gulf distributors buy well below their minimums, revenue falls to about $15 million in 2027 and losses reach about $14 million before a restructuring or wind-down in 2028. The business is worth about -$15 million, and after debt about -$21.5 million, or -$1.31 per share. In this case the lender's claim and warrant would leave common shareholders essentially nothing. Bull case. The distributors largely meet their minimums, NXC renews at about its 2025 level, and revenue reaches about $45-48 million in 2027-2028 at a 43% gross margin, which is roughly breakeven. The Gulf Medical agreement's automatic one-year extension (triggered if its minimums are met) carries the story into 2029. The business is worth about +$2 million, but after $6.2 million of net debt the shares are still worth about -$0.26. Conclusion. In all three cases the company is worth less than it owes once its likely cash burn is counted. Even the good outcome only reaches breakeven, and shareholders would need to put in more money. The shares would become investable only if the company shows it can produce cash on its own, not just grow revenue. If it did, with sustained profits of about $4 million a year, we estimate the shares would be worth roughly $1.10 on a fully diluted basis. Given the customer concentration, the dilution already in place and the short record, the margin-of-safety price is around $0.40. What would prove this analysis wrong: NXC renewing on larger committed volumes, the Gulf distributors meeting their minimums in 2026-2027, or operating costs falling back toward the 2025 level ($13 million) while sales keep growing. Any of these would move the business toward breakeven sooner than we assume. Stockholders' equity was $2.2 million at June 30, 2026, below the $2.5 million Nasdaq equity standard, so continued listing relies on the exchange's market-value alternative. The company reports no listing notice. Management states it has enough cash for at least 12 months.